...
首页> 外文期刊>Journal of Gynecologic Oncology >Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer
【24h】

Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer

机译:血清人类组织激肽释放酶和CA-125的组合检测上皮性卵巢癌

获取原文
           

摘要

Objective To determine the predictive accuracy of the combined panels of serum human tissue kallikreins (hKs) and CA-125 for the detection of epithelial ovarian cancer. Methods Serum specimens collected from 5 Indonesian centers and 1 Vietnamese center were analyzed for CA-125, hK6, and hK10 levels. A total of 375 specimens from patients presenting with ovarian tumors, which include 156 benign cysts, 172 epithelial ovarian cancers (stage I/II, n=72; stage III/IV, n=100), 36 germ cell tumors and 11 borderline tumors, were included in the study analysis. Receiver operating characteristic analysis were performed to determine the cutoffs for age, CA-125, hK6, and hK10. Sensitivity, specificity, negative, and positive predictive values were determined for various combinations of the biomarkers. Results The levels of hK6 and hK10 were significantly elevated in ovarian cancer cases compared to benign cysts. Combination of 3 markers, age/CA-125/hk6 or CA-125/hk6/hk10, showed improved specificity (100%) and positive predictive value (100%) for prediction of ovarian cancer, when compared to the performance of single markers having 80-92% specificity and 74-87% positive predictive value. Four-marker combination, age/CA-125/hK6/hK10 also showed 100% specificity and 100% positive predictive value, although it demonstrated low sensitivity (11.9%) and negative predictive value (52.8%). Conclusion The combination of human tissue kallikreins and CA-125 showed potential for improving prediction of epithelial ovarian cancer in patients presenting with ovarian tumors.
机译:目的确定血清人组织激肽释放酶(hKs)和CA-125联合检测小组在上皮性卵巢癌中的预测准确性。方法分析5个印尼中心和1个越南中心的血清标本的CA-125,hK6和hK10水平。共有375例来自卵巢肿瘤患者的标本,包括156个良性囊肿,172个上皮性卵巢癌(I / II期,n = 72; III / IV期,n = 100),36个生殖细胞肿瘤和11个交界性肿瘤,被纳入研究分析。进行接收器工作特性分析以确定年龄,CA-125,hK6和hK10的临界值。确定了各种生物标志物组合的敏感性,特异性,阴性和阳性预测值。结果与良性囊肿相比,卵巢癌病例中hK6和hK10的水平显着升高。与单一标记物的性能相比,年龄/ CA-125 / hk6或CA-125 / hk6 / hk10 3种标记物的组合显示出更好的特异性(100%)和阳性预测值(100%)预测卵巢癌具有80-92%的特异性和74-87%的阳性预测值。年龄/ CA-125 / hK6 / hK10四标记组合也显示出100%的特异性和100%的阳性预测值,尽管它显示出低的敏感性(11.9%)和阴性的预测值(52.8%)。结论人体组织激肽释放酶和CA-125的组合显示出改善卵巢肿瘤患者上皮性卵巢癌预测的潜力。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号